Breaking News, Collaborations & Alliances

ProThera, Takeda Enter Anti-Inflammatory Alliance

To develop a novel plasma-derived Inter-alpha Inhibitor Proteins therapy for the treatment of acute inflammatory conditions

By: Contract Pharma

Contract Pharma Staff

ProThera Biologics, Inc. and Takeda Pharmaceutical Co. have entered into a global licensing agreement to develop a novel plasma-derived Inter-alpha Inhibitor Proteins (IAIP) therapy for the treatment of acute inflammatory conditions. Early research has indicated that this IAIP technology has the potential to deliver a highly innovative, disease-modifying treatment for a range of acute inflammatory diseases. IAIP are naturally occurring proteins that circulate in the blood, and extensive res...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters